Strides Pharma Science Limited (STAR.NS)
Strides Pharma Science Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Bengaluru, KA, IN. The stock last traded at $967.80, down 2.16% on the session, giving a market capitalisation of $89.20B. Its beta of 0.39 implies it has historically moved less than the broad market.
Strides Pharma Science Limited is a pharmaceutical company that focuses on the development, production, and worldwide commercialization of medicinal products. Its extensive global footprint spans Africa, Australia, North America, Europe, Asia, India, and various other international markets. The company's operations are structured into two distinct segments: Pharmaceutical and Biopharmaceutical. It provides a diverse range of generic pharmaceuticals, available in multiple formats including tablets, hard and soft gelatin capsules, sachets, liquids, nasal sprays, powders, solids, ointments, and creams. Furthermore, Strides Pharma Science creates branded generic offerings for treating chronic ailments such as women's health issues, central nervous system disorders, cardiovascular conditions, diabetes, dermatological concerns, and probiotic support, marketed under brands like Renerve, Unibrol, Combiart, Duotab, and Vitafer. For institutional business, the company supplies drugs targeting infectious diseases, including anti-retrovirals, anti-malarials, anti-tuberculosis, and Hepatitis treatments. Incorporated in 1990, the company is headquartered in Bengaluru, India. It was formerly known as Strides Shasun Limited before adopting its current name in July 2018.
Strides Pharma Science Limited is most often compared with the following Healthcare names: